Skip to main content
Clinical Trials/NCT02994277
NCT02994277
Completed
Not Applicable

Pilot Study of Automatic Glycaemic Correction Systems (Closed-loop) in Patients With Type 1 Diabetes Mellitus With Continuous Subcutaneous Insulin Infusion

Hospital Italiano de Buenos Aires0 sites5 target enrollmentNovember 1, 2016
ConditionsDiabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes
Sponsor
Hospital Italiano de Buenos Aires
Enrollment
5
Primary Endpoint
System connectivity
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

The purpose of this study is to use closed-loop systems with the algorithms designed by the University of Virginia and by the Instituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) to determine the infusion of insulin in a prolonged period of time in patients with type 1 diabetes mellitus (T1DM).

Detailed Description

Aims: 1. To test University of Virginia closed-loop algorithm with meal announcement for 36 hours at our facilities. 2. To test the ability of the closed-loopInstituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) algorithm without meal announcement to maintain glucose control for 2 periods of 12 hours In both cases, the adequate operation of the system will be considered verified if the system works properly at least 80% of the total connection time .

Registry
clinicaltrials.gov
Start Date
November 1, 2016
End Date
July 7, 2017
Last Updated
7 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Waldo Horacio Belloso

MD

Hospital Italiano de Buenos Aires

Eligibility Criteria

Inclusion Criteria

  • Patient have been diagnosed with T1DM at least two years ago and have been using an insulin pump and a CGM for at least 6 months prior to the trial first visit.
  • Patient is \>18 and \<65 years.
  • Patient has HbA1c \> 6.5 % and \< 10%.
  • Woman in premenopausal age agrees to use contraceptive methods.
  • Woman in premenopausal age has negative B-HCG in the tests performed in the trial.
  • Patient is trained in carbohydrates counting.
  • Patient has signed informed consent and has the ability to understand the nature and intent of the study including the ability to comply with study procedures and is willing to keep scheduled visits.

Exclusion Criteria

  • Patient has been hospitalized for diabetic ketoacidosis in the last 12 months.
  • Patient has experienced severe hypoglycemia with loss of consciousness in the last 12 months.
  • Patient has a history of coronary disease or cardiac failure.
  • Patient with uncontrolled arterial hypertension.
  • Patient with a condition that makes the researcher believe that it might increase the chance of hypoglycemia.
  • Patient has symptoms compatible with an active infectious disease.
  • Patient has Cystic Fibrosis.
  • Pregnant women, or women with the intention of getting pregnant; women breastfeeding.
  • Patient has been hospitalized for psychiatric treatment in the last 6 months.
  • Patient with a diagnosis of an adrenal disease.

Outcomes

Primary Outcomes

System connectivity

Time Frame: 36 hours

Adequate operation of the system will be considered verified if the system works properly at least 80% of the total connection time.

Secondary Outcomes

  • Number of all hypoglycaemic events (syntomatic and non syntomatic)(36 hours)
  • Comparison of glycaemic profiles during the trial with glycaemic profiles in the days before the trial(36 hours)
  • Meal composition's effect in the efficacy of the system to control glycaemia(36 hours)
  • Technical fail rate(36 hours)
  • Percentage of time in glycaemia between 70-180 mg/dl(36 hours)
  • Percentage of time in glycaemia between 181-250 mg/dl(36 hours)
  • Percentage of time in hypoglycaemia defined as <70 mg/dl(36 hours)
  • Percentage of time in hyperglycaemia defined as >180 mg/dl(36 hours)

Similar Trials